FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085325173> ?p ?o ?g. }

• W3085325173 endingPage "3918" @default.
• W3085325173 startingPage "3910" @default.
• W3085325173 abstract "Heart failure (HF) and type 2 diabetes (T2D), common co-morbidities, translate into worse patient prognoses and higher direct costs than for either condition alone. Empagliflozin has been shown to markedly reduce cardiovascular (CV) deaths and HF hospitalizations (HHF) in HF patients with T2D. This study evaluated the lifetime cost-effectiveness of supplementing standard of care (SoC) with empagliflozin, relative to SoC alone, in HF patients with T2D from the UK payer perspective.An existing discrete-event simulation model was adapted for the economic evaluation. Risk equations developed from time-dependent parametric survival analyses using patient-level HF subpopulation data from the EMPA-REG OUTCOME trial were employed to predict CV and renal events. Non-CV death, utility weights, and costs were drawn from UK sources. Quality-adjusted life years (QALYs) and costs were discounted at 3.5% per annum. Relative to SoC, empagliflozin with SoC yielded fewer first HHF, recurrent HHF, CV death, and non-fatal myocardial infarction but more non-fatal stroke events. Empagliflozin with SoC vs. SoC alone was associated with increased average life expectancy (10.80 vs. 9.59 LYs) and quality of life (6.27 vs. 5.62 QALYs), though at higher lifetime cost (£18 197 vs. £16 829) per person, resulting in an incremental cost-effectiveness ratio of £2093 per QALY. The probability of empagliflozin being cost-effective in the HF subpopulation at a £20 000 per QALY willingness-to-pay threshold was 91%.This analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost-effective use of UK healthcare resources and may provide long-term health benefits to patients." @default.
• W3085325173 created "2020-09-21" @default.
• W3085325173 creator A5003188866 @default.
• W3085325173 creator A5003810679 @default.
• W3085325173 creator A5016763799 @default.
• W3085325173 creator A5027970978 @default.
• W3085325173 creator A5028502811 @default.
• W3085325173 creator A5034066967 @default.
• W3085325173 creator A5059690284 @default.
• W3085325173 creator A5060236174 @default.
• W3085325173 creator A5073440750 @default.
• W3085325173 creator A5074225876 @default.
• W3085325173 creator A5081421617 @default.
• W3085325173 creator A5082520060 @default.
• W3085325173 date "2020-09-10" @default.
• W3085325173 modified "2023-09-30" @default.
• W3085325173 title "Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure" @default.
• W3085325173 cites W1524829680 @default.
• W3085325173 cites W2022670796 @default.
• W3085325173 cites W2041508558 @default.
• W3085325173 cites W2061989334 @default.
• W3085325173 cites W2112787506 @default.
• W3085325173 cites W2123026839 @default.
• W3085325173 cites W2126252058 @default.
• W3085325173 cites W2146264128 @default.
• W3085325173 cites W2273304042 @default.
• W3085325173 cites W2399249038 @default.
• W3085325173 cites W2497926742 @default.
• W3085325173 cites W2540798315 @default.
• W3085325173 cites W2626446274 @default.
• W3085325173 cites W2784848586 @default.
• W3085325173 cites W2788613077 @default.
• W3085325173 cites W2793795908 @default.
• W3085325173 cites W2900413769 @default.
• W3085325173 cites W2906642016 @default.
• W3085325173 cites W2961971687 @default.
• W3085325173 cites W2974260792 @default.
• W3085325173 cites W2975832089 @default.
• W3085325173 doi "https://doi.org/10.1002/ehf2.12985" @default.
• W3085325173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7754962" @default.
• W3085325173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32909680" @default.
• W3085325173 hasPublicationYear "2020" @default.
• W3085325173 type Work @default.
• W3085325173 sameAs 3085325173 @default.
• W3085325173 citedByCount "15" @default.
• W3085325173 countsByYear W30853251732021 @default.
• W3085325173 countsByYear W30853251732022 @default.
• W3085325173 countsByYear W30853251732023 @default.
• W3085325173 crossrefType "journal-article" @default.
• W3085325173 hasAuthorship W3085325173A5003188866 @default.
• W3085325173 hasAuthorship W3085325173A5003810679 @default.
• W3085325173 hasAuthorship W3085325173A5016763799 @default.
• W3085325173 hasAuthorship W3085325173A5027970978 @default.
• W3085325173 hasAuthorship W3085325173A5028502811 @default.
• W3085325173 hasAuthorship W3085325173A5034066967 @default.
• W3085325173 hasAuthorship W3085325173A5059690284 @default.
• W3085325173 hasAuthorship W3085325173A5060236174 @default.
• W3085325173 hasAuthorship W3085325173A5073440750 @default.
• W3085325173 hasAuthorship W3085325173A5074225876 @default.
• W3085325173 hasAuthorship W3085325173A5081421617 @default.
• W3085325173 hasAuthorship W3085325173A5082520060 @default.
• W3085325173 hasBestOaLocation W30853251731 @default.
• W3085325173 hasConcept C112930515 @default.
• W3085325173 hasConcept C126322002 @default.
• W3085325173 hasConcept C134018914 @default.
• W3085325173 hasConcept C138411078 @default.
• W3085325173 hasConcept C184834754 @default.
• W3085325173 hasConcept C185592680 @default.
• W3085325173 hasConcept C194828623 @default.
• W3085325173 hasConcept C199289684 @default.
• W3085325173 hasConcept C207103383 @default.
• W3085325173 hasConcept C2775887513 @default.
• W3085325173 hasConcept C2777180221 @default.
• W3085325173 hasConcept C2778198053 @default.
• W3085325173 hasConcept C2779900020 @default.
• W3085325173 hasConcept C2780652884 @default.
• W3085325173 hasConcept C3019080777 @default.
• W3085325173 hasConcept C44249647 @default.
• W3085325173 hasConcept C515549039 @default.
• W3085325173 hasConcept C555293320 @default.
• W3085325173 hasConcept C64332521 @default.
• W3085325173 hasConcept C71924100 @default.
• W3085325173 hasConceptScore W3085325173C112930515 @default.
• W3085325173 hasConceptScore W3085325173C126322002 @default.
• W3085325173 hasConceptScore W3085325173C134018914 @default.
• W3085325173 hasConceptScore W3085325173C138411078 @default.
• W3085325173 hasConceptScore W3085325173C184834754 @default.
• W3085325173 hasConceptScore W3085325173C185592680 @default.
• W3085325173 hasConceptScore W3085325173C194828623 @default.
• W3085325173 hasConceptScore W3085325173C199289684 @default.
• W3085325173 hasConceptScore W3085325173C207103383 @default.
• W3085325173 hasConceptScore W3085325173C2775887513 @default.
• W3085325173 hasConceptScore W3085325173C2777180221 @default.
• W3085325173 hasConceptScore W3085325173C2778198053 @default.
• W3085325173 hasConceptScore W3085325173C2779900020 @default.
• W3085325173 hasConceptScore W3085325173C2780652884 @default.
• W3085325173 hasConceptScore W3085325173C3019080777 @default.
• W3085325173 hasConceptScore W3085325173C44249647 @default.

• next